| 29.04 16:10 | dpa-AFX: Abbott's Dissolving Stent For People With Chronic Limb-Threatening Ischemia Gets FDA Nod |
| 29.04 15:04 | dpa-AFX: *FDA OKS ABBOTT'S ESPRIT BTK EVEROLIMUS ELUTING RESORBABLE SCAFFOLD SYSTEM FOR CHRONIC LIMB-THREATENING ISCHEMIA |
| 17.04 22:15 | MÄRKTE USA/Leichter - Halbleiterwerte unter Druck |
| 17.04 18:16 | MÄRKTE USA/Leichter - Halbleiterwerte unter Druck |
| 17.04 15:42 | MÄRKTE USA/Etwas fester - Sinkende Marktzinsen stützen Aktien |
| 17.04 15:31 | dpa-AFX: *ABBOTT LABORATORIES -1% WENIG BEWEGT NACH QUARTALSZAHLEN |
| 17.04 14:42 | MÄRKTE USA/Gut behauptet - ASML könnte Technologiewerte bremsen |
| 17.04 13:52 | dpa-AFX: ROUNDUP: Abbott Laboratories Q1 Earnings Fall, But Ups Annual Earnings Outlook |
| 17.04 13:37 | dpa-AFX: *ABBOTT NARROWS 2024 ORGANIC SALES GROWTH GUIDANCE RANGE, EXCL. COVID-19 TESTING-RELATED SALES, TO 8.5% TO 10.0% |
| 17.04 13:37 | dpa-AFX: *ABBOTT LABORATORIES VORBÖRSLICH -0,2% NACH QUARTALSZAHLEN |
| 17.04 13:36 | dpa-AFX: *ABBOTT PROJECTS FULL-YEAR EPS OF $3.25 TO $3.40 AND ADJ. EPS OF $4.55 TO $4.70 |
| 17.04 13:35 | dpa-AFX: *ABBOTT PROJECTS Q2 EPS OF $0.69 TO $0.73, ADJ. EPS OF $1.08 TO $1.12 |
| 17.04 13:34 | dpa-AFX: *ABBOTT Q1 NET SALES $9.96 BLN VS $9.75 BLN PRIOR YEAR |
| 17.04 13:34 | dpa-AFX: *ABBOTT Q1 NET EARNINGS $1.23 BLN VS $1.32 BLN PRIOR YEAR |
| 17.04 13:33 | dpa-AFX: *ABBOTT Q1 ADJ. EPS $0.98 VS $1.03 PRIOR YEAR |
| 17.04 13:33 | dpa-AFX: Abbott Laboratories Reports Fall In Q1 Bottom Line |
| 17.04 13:33 | dpa-AFX: *ABBOTT Q1 EPS DECLINES $0.70 FROM $0.75 PRIOR YEAR |
| 17.04 13:32 | dpa-AFX: *ABBOTT NARROWS FULL-YEAR 2024 EPS GUIDANCE RANGE |
| 17.04 13:32 | dpa-AFX: *ABBOTT REPORTS Q1 EPS OF $0.70, ADJ EPS OF $0.98 |
| 17.04 12:18 | MARKT USA/Etwas fester - ASML könnte Technologiewerte bremsen |
|
|
